Skip to main content
ALLURION TECHNOLOGIES, INC. logo

ALLURION TECHNOLOGIES, INC. — Investor Relations & Filings

Ticker · ALUR ISIN · US02008G1022 US Human health and social work activities
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US ALUR

About ALLURION TECHNOLOGIES, INC.

https://www.allurion.com/en

Allurion Technologies, Inc. is a company focused on ending obesity through its comprehensive weight-loss platform, the Allurion Program. The program's core component is a procedure-less, swallowable gastric balloon that is placed during an outpatient visit and passes naturally after approximately four months. This device is integrated into a full-stack solution that includes a digital ecosystem for real-time progress tracking via connected devices, an AI-powered coaching assistant, and personalized support from a multidisciplinary team of healthcare professionals. The platform is designed to promote sustainable, metabolically healthy weight loss by combining appetite regulation with behavioral change support. It can function as a standalone treatment or in combination with other therapies, including the company's AI-native compounded GLP-1 program.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 89% confidence The document is a Form 8-K current report under Section 13 or 15(d) of the Exchange Act, specifically Item 4.01 disclosing the dismissal of Deloitte & Touche LLP and appointment of a new independent registered public accounting firm. It does not contain the full audit report itself or detailed financial statements, nor does it cover management changes, dividends, or capital transactions. It is a regulatory compliance filing to inform the SEC and investors of a change in certifying accountant, which does not fit into any specific category other than the general “Regulatory Filings” catch-all.
2026-05-27 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
Annual Report FY 2025
2026-03-30 English
8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2026, by Allurion Technologies, Inc. The key content is the announcement of receipt of a delisting notice from the NYSE due to non-compliance with listing standards and the company's intent to appeal. The document discusses the delisting process, potential impacts, and ongoing efforts to regain compliance. There are no financial statements or detailed financial data included, and the document primarily serves as an official notice of the delisting event and related company actions. This matches the definition of a Delisting Announcement (DLST).
2026-03-02 English
8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements. The text describes the company's entry into a material definitive agreement related to warrant exercise inducement, amendments to existing warrants, and issuance of new warrants. It includes details about the transaction, financial advisor fees, and registration statements. There are no financial statements or comprehensive financial data presented, only disclosures about a financing-related transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 6777 characters, sufficient to contain substantive information about the financing event. Therefore, the correct classification is CAP with high confidence.
2026-02-25 English
8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 23, 2026. It announces FDA approval of a product and includes a press release as Exhibit 99.1. The text explicitly states that the information is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not "filed" for purposes of Section 18 of the Exchange Act. The document does not contain financial statements or detailed financial data but rather a regulatory announcement and a press release. The length is 6969 characters, which is relatively short and consistent with a regulatory filing rather than a full financial report. The content is primarily an announcement of a material event (FDA approval) and a press release, typical of a Regulatory Filing (RNS). Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-23 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.